Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.

被引：0
|
作者：
Yang, Hongbo
Qi, Cynthia Zhengyun
Dalal, Anand
Bollu, Vamsi
Zhang, Jie
Zhang, Su
Lim, Stephen
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19551
引用
收藏
页数：3
相关论文
共 50 条
  • [21] The Outcome of Tisagenlecleucel (Tisa-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) CD-19 CAR-T Cell Therapy in Relapsed/Refractory NHL, Real World Data, Single Institution Experience
    Alasbali, Reem
    Nasiri, Abdulrahman
    Adam, Alfadil
    Alhayli, Saud
    Chaudhri, Naeem A.
    Alshaibani, Alfadel
    Albabtain, Abdulwahab
    Samarkandi, Hadeel
    Saad, Ayman
    Alamer, Abdullah
    Elhassan, Tusneem Ahmed M.
    Alzahrani, Hazza A.
    Ahmed, Syed Osman
    Rasheed, Walid
    Elfakih, Riad
    Aljurf, Mahmoud
    Ali, D. Alahmari
    BLOOD, 2023, 142
  • [22] AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
    Diakite, I
    Lin, V. W.
    Klijn, S.
    Navale, L.
    Purdum, A. G.
    Fenwick, E.
    Botteman, M.
    van Hout, B.
    VALUE IN HEALTH, 2019, 22 : S41 - S41
  • [23] Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.
    Locke, Frederick L.
    Siddiqi, Tanya
    Jacobson, Caron Alyce
    Ghobadi, Armin
    Ahmed, Sairah
    Miklos, David Bernard
    Perales, Miguel-Angel
    Munoz, Javier
    Logan, Brent
    Hu, Zhen-Huan
    Miao, Harry H.
    Singh, Kanwarjit
    Shah, Jina
    Xu, Hairong
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] PRELIMINARY RESULTS OF THE EARLY USE OF CORTICOSTEROIDS WITH AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS DIAGNOSED WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)
    Max, Topp S.
    Van Meerten, T.
    Wermke, M.
    Pieternella, Lugtenburg J.
    Monique, Minnema C.
    Kevin, Song W.
    Thieblemont, C.
    Jiang, Y.
    Plaks, V
    Kerber, A.
    Kersten, M. J.
    HAEMATOLOGICA, 2019, 104 : 98 - 98
  • [25] ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).
    Oluwole, Olalekan O.
    Bishop, Michael Russell
    Gisselbrecht, Christian
    Gordon, Leo I.
    Kersten, Marie Jose
    Maloney, David G.
    Schmitz, Norbert
    Barrigon, Maria Dolores Caballero
    Kuruvilla, John
    Song, Kevin W.
    Jacobson, Caron A.
    Nastoupil, Loretta J.
    Riedell, Peter
    Jiang, Yizhou
    Rossi, John M.
    Lee, Lillian
    Cheng, Paul C.
    Locke, Frederick Lundry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Health Utilities for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL): Ad Hoc Analysis From an Axicabtagene Ciloleucel (Axi-cel) Safety Management Study
    Lin, Vincent W.
    Jiang, Yizhou
    Chuang, Ling Hsiang
    Navale, Lynn
    Cheng, Paul
    Purdum, Anna
    BONE MARROW TRANSPLANTATION, 2018, 53 : 879 - 879
  • [27] CLINICAL PREDICTORS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): A SYSTEMATIC LITERATURE REVIEW (SLR) AND META-ANALYSIS
    Sanderson, R.
    Munoz, J.
    Wang, Y.
    Kanters, S.
    Limbrick-Oldfield, E.
    Miao, H.
    Spooner, C.
    Baro, E.
    Xu, H.
    Jacobson, C.
    VALUE IN HEALTH, 2022, 25 (12) : S47 - S48
  • [28] Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction
    Locke, Frederick L.
    Jacobson, Caron
    Ma, Long
    Dong, Hua
    Hu, Zhen-Huan
    Siddiqi, Tanya
    Ahmed, Sairah
    Ghobad, Armin
    Miklos, David B.
    Lin, Yi
    Perales, Miguel-Angel
    Lunning, Matthew A.
    Herr, Megan M.
    Hill, Brian T.
    Ganguly, Siddhartha
    Mirza, Abu-Sayeef
    Nikiforow, Sarah
    Xu, Hairong
    Pasquini, Marcelo C.
    BLOOD, 2021, 138
  • [29] A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry
    Bachy, Emmanuel
    Le Gouill, Steven
    Di Blasi, Roberta
    Sesques, Pierre
    Cartron, Guillaume
    Beauvais, David
    Roulin, Louise
    Gros, Francois Xavier
    Sylvain, Choquet
    Bories, Pierre
    Rubio, Marie Therese
    Casasnovas, Rene-Olivier
    Bay, Jacques-Olivier
    Mohty, Mohamad
    Joris, Magalie
    Gastinne, Thomas
    Tudesq, Jean Jacques
    Chaillol, Isabelle
    Broussais, Florence
    Thieblemont, Catherine
    Houot, Roch
    Morschhauser, Franck
    BLOOD, 2021, 138
  • [30] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
    Kenderian, Saad S.
    Oluwole, Olalekan O.
    McCarthy, Philip L.
    Reshef, Ran
    Shiraz, Parveen
    Ahmed, Omar
    Le Gall, John
    Nahas, Myrna
    Tang, Lily
    Neelapu, Sattva S.
    BLOOD, 2020, 136
12345